Metraipolis › archive › dc_7f5010ae3e90

Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: Insights from naïve and switch patients — Europe PMC PMID:40957770

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40957770
DOI
10.1016/j.neurot.2025.e00724
License (as archived)
solo-consultazione
Archived
2026-11-09T23:22:06.743Z
SHA-256 of the archived text
d7b581349b218f5ed25a9b3edb191881260ee6a75b10085ff14716ca28b19a0c
Stable URL of this page
https://metraipolis.com/documento/dc_7f5010ae3e90

How to cite

Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: Insights from naïve and switch patients — Europe PMC PMID:40957770 — Europe PMC (en), https://europepmc.org/article/MED/40957770 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7f5010ae3e90 (Metraipolis archive dc_7f5010ae3e90, sha256 d7b581349b218f5ed25a9b3edb191881260ee6a75b10085ff14716ca28b19a0c)
BibTeX
@misc{dc7f5010ae3e90,
  title = {Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: Insights from naïve and switch patients — Europe PMC PMID:40957770},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40957770},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7f5010ae3e90; sha256 d7b581349b218f5ed25a9b3edb191881260ee6a75b10085ff14716ca28b19a0c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40957770. Agents can read the archived copy with the MCP tool read_document.